Josh Drago, MD, MS
LightNews LightNews
banner
joshdragomd.bsky.social
Josh Drago, MD, MS
@joshdragomd.bsky.social
260 followers 75 following 7 posts
Breast Cancer Specialist
Clinical and Translational Investigator
Memorial Sloan Kettering Cancer Center
Posts Replies Media Videos
joshdragomd.bsky.social
In this manuscript, online today in Cancer Discovery, we investigate target-mediated resistance to ADCs, and propose ways to overcome it.

aacrjournals.org/cancerdiscov...
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and Binding
Abstract. T-DXd is clinically beneficial in HER2 positive and HER2 low metastatic breast cancer. However, therapeutic resistance emerges over time in most patients, with poorly defined resistance mech...
aacrjournals.org
November 10, 2025 at 4:55 PM
Reposted by Josh Drago, MD, MS
saratchandarlapaty.bsky.social
Published online today - work from our team led by Avantika Gupta, revealing how APOBEC3 mutagenesis promotes resistance to several targeted therapies in breast cancer. Check it out!

urldefense.com/v3/__https:/...
APOBEC3 mutagenesis drives therapy resistance in breast cancer
Nature Genetics - Analysis of a large cohort of metastatic breast cancer samples shows that APOBEC mutational signatures are enriched in post-treatment samples. APOBEC activity was also associated...
urldefense.com
May 16, 2025 at 11:33 AM
Reposted by Josh Drago, MD, MS
saratchandarlapaty.bsky.social
Fantastic presentation #SABCS by @avantikagupta.bsky.social on apobec3 in breast cancer. Demonstrating the role of this process in promoting therapy resistance.
December 12, 2024 at 5:51 PM
Reposted by Josh Drago, MD, MS
drsarahsammons.bsky.social
RSclin for node positive ER+ patients is validated! I hope it’s available to use soon.

Always helpful to have tools to estimate recurrence and chemo benefit in these hard conversations with patients!

ascopubs.org/doi/10.1200/...
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor–Positive, Node-Positive Breast Cancer
PURPOSEClinicopathological factors and the 21-gene Oncotype DX Breast Recurrence Score (RS) test both influence prognosis. Our goal was to develop a new tool, RSClinN+, to individualize recurrence ris...
ascopubs.org
December 9, 2024 at 11:24 AM
Reposted by Josh Drago, MD, MS
tmprowell.bsky.social
NEW #Oncology:
EGFR expression mediates resistance to T-DXd (EGFR overexpression ⬇️ HER2 homodimerization & HER2/ADC internalization)

Combining with EGFR mAbs restored HER2/ADC trafficking & ⬆️ activity in nonclinical models

#DrugDevelopment #OncoSky

www.cell.com/cell-reports...
EGFR-directed antibodies promote HER2 ADC internalization and efficacy
Gupta et al. demonstrate that high EGFR expression mediates resistance to HER2 antibody drug conjugates (ADCs) including trastuzumab deruxtecan (T-DXd) by limiting HER2/ADC internalization. The additi...
www.cell.com
November 12, 2024 at 12:33 PM